A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

I saw the news recently that the Food and Drug Administration is proposing to remove a popular ingredient in over-the-counter ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

"We are pleased the FDA has accepted our NDA for Bumetanide Nasal Spray," said Benjamin Esque, CEO of Corstasis Therapeutics ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

A groundbreaking approach led by a team of scientists, including Rice University chemist James Tour, has the potential to ...

Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Kenox Pharmaceuticals Inc., a company dedicated to developing innovative Orally Inhaled and Nasal Drug Products (OINDPs), has ...

The expansion is a natural progression for Upperton who already develops and manufactures small molecule and biological, ...